Masimo (NASDAQ:MASI) Releases FY 2024 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 3.800-4.000 for the period, compared to the consensus estimate of 3.880. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion.

Wall Street Analyst Weigh In

MASI has been the topic of several recent analyst reports. BTIG Research increased their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Masimo in a research note on Friday, October 18th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.33.

Masimo Stock Performance

Shares of MASI stock traded up $0.34 during trading hours on Tuesday, hitting $141.05. The stock had a trading volume of 273,214 shares, compared to its average volume of 674,230. The firm has a market capitalization of $7.50 billion, a PE ratio of 95.72 and a beta of 0.99. Masimo has a twelve month low of $75.36 and a twelve month high of $153.93. The stock’s 50 day moving average is $127.74 and its 200 day moving average is $124.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period last year, the company earned $0.62 earnings per share. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, research analysts forecast that Masimo will post 3.88 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.